Gallium-68 fibroblast activation protein inhibitor (68Ga-FAPI) positron emission tomography/computed tomography (PET/CT) versus 18F-fluorodeoxyglucose (18F-FDG) PET/CT for pancreatic cancer: A feasibility study

I-MED Radiology Network0 个研究点目标入组 10 人开始时间: 2022年5月13日最近更新: 2023年6月26日

适应症

试验速览

暂无简介。

•Inclusion criteria
•Minimum of 18 years of age
•Histologically or cytologically confirmed pancreatic cancer
•Under consideration for surgical resection by a Wesley HPB surgeon
•No treatment with chemotherapy, external beam radiation, immunotherapy and/or angiogenesis inhibitors for up to four weeks prior to study PET/CT scans
•Adequate renal function (A patient’s eGFR needs to be greater than 35mL/min/1.73m2 to receive CT contrast).
•Ability to understand and willingness to sign a written informed consent document
•Willing and able to comply with the two required PET/CT scans
•This patient group has been selected as they represent a group in which current imaging methods for staging/restaging presents an unmet diagnostic challenge.

•Exclusion criteria
•Pancreatic disease too advanced for surgical resection to be considered standard care
•Concurrent malignancies, except non-melanoma skin cancers
•Pregnant or breast feeding
•Participation would delay imminent conventional treatment
•History of allergic reactions attributed to compounds of similar chemical or biologic composition to FAPI, FDG or intravenous iodinated contrast media
•Involvement in a clinical trial with an investigational agent which may reasonably interfere with the PET/CT imaging
•Uncontrolled intercurrent illness which may reasonably interfere with PET/CT imaging, including, but not limited to, active infection or inflammatory process

发起方

I-MED Radiology Network